rituximab

rituximab is a medication used to treat certain types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and follicular lymphoma, in combination with chemotherapy and as a single agent. It is also used to treat rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, in combination with methotrexate and glucocorticoids. The development of rituximab is attributed to the work of Napoleone Ferrara and Arie Belldegrun at Genentech, in collaboration with City of Hope National Medical Center and University of California, Los Angeles. The medication has been approved by the US Food and Drug Administration and the European Medicines Agency for various indications, including chronic lymphocytic leukemia and Waldenström's macroglobulinemia.

● Introduction

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of B cells. The medication is produced by Biogen Idec and Roche Holding, and is marketed under the brand name MabThera in Europe and Australia, and as Rituxan in the United States and Canada. The development of rituximab has been influenced by the work of researchers at Stanford University, University of California, San Francisco, and National Institutes of Health. The medication has been used in combination with other therapies, such as cyclophosphamide, doxorubicin, and vincristine, to treat various types of cancer, including Hodgkin's lymphoma and multiple myeloma.

● Mechanism_of_action

The mechanism of action of rituximab involves the binding of the antibody to the CD20 antigen on the surface of B cells, leading to the depletion of these cells through apoptosis and complement-dependent cytotoxicity. This process is mediated by the activation of complement system components, such as C1q and C3b, and the recruitment of natural killer cells and macrophages. The medication has been shown to induce apoptosis in B cells through the activation of caspase-3 and caspase-8, and to inhibit the proliferation of these cells through the downregulation of cyclin D2 and cyclin E. Researchers at Harvard University, University of Pennsylvania, and University of Chicago have contributed to the understanding of the mechanism of action of rituximab.

● Medical_uses

Rituximab is used to treat various types of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma, as well as chronic lymphocytic leukemia and Waldenström's macroglobulinemia. The medication is also used to treat rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, in combination with methotrexate and glucocorticoids. The use of rituximab in the treatment of autoimmune hemolytic anemia and immune thrombocytopenia has been investigated by researchers at Mayo Clinic, Cleveland Clinic, and University of California, Los Angeles. The medication has been approved by the US Food and Drug Administration and the European Medicines Agency for various indications, including relapsed or refractory non-Hodgkin's lymphoma.

● Side_effects

The side effects of rituximab include infusion reactions, such as fever, chills, and hypotension, as well as neutropenia and thrombocytopenia. The medication can also cause infections, such as pneumonia and sepsis, particularly in patients with compromised immune systems. The risk of progressive multifocal leukoencephalopathy (PML) has been associated with the use of rituximab, particularly in patients with HIV/AIDS or lymphoma. Researchers at National Cancer Institute, Centers for Disease Control and Prevention, and World Health Organization have investigated the side effects of rituximab.

● History

The development of rituximab began in the 1980s, when researchers at City of Hope National Medical Center and Genentech discovered the CD20 antigen and developed a monoclonal antibody against it. The medication was first approved by the US Food and Drug Administration in 1997 for the treatment of relapsed or refractory non-Hodgkin's lymphoma. Since then, rituximab has been approved for various indications, including chronic lymphocytic leukemia and rheumatoid arthritis. The medication has been marketed by Biogen Idec and Roche Holding, and has been used in combination with other therapies, such as chemotherapy and radiation therapy, to treat various types of cancer.

● Pharmacology

The pharmacology of rituximab involves the binding of the antibody to the CD20 antigen on the surface of B cells, leading to the depletion of these cells through apoptosis and complement-dependent cytotoxicity. The medication has a half-life of approximately 20 days, and is eliminated primarily through the liver and kidneys. The pharmacokinetics of rituximab have been studied by researchers at University of California, San Francisco, Stanford University, and National Institutes of Health. The medication has been shown to induce immunogenicity in some patients, leading to the development of antibodies against the CD20 antigen. Researchers at Harvard University, University of Pennsylvania, and University of Chicago have contributed to the understanding of the pharmacology of rituximab. Category:Monoclonal antibodies